--- a
+++ b/clusters/9knumclustersv2/clust_146.txt
@@ -0,0 +1,169 @@
+Patients with a history of hepatic sinusoid obstructive syndrome (veno-occlusive disease) within the prior  months
+History of reversible posterior leukoencephalopathy syndrome (RPLS)
+Trisomy  (Down syndrome)
+Patients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
+Patients with Down syndrome
+Patients with Down syndrome are not eligible
+Down syndrome
+Patients with down syndrome are excluded from this study
+Patients with known symptomatic Fanconi anemia (FA), ataxia-telangiectasia (A-T) syndrome, Bloom syndrome (BS) and Nijmegen breakage syndrome (NBS) are not eligible (asymptomatic carriers are acceptable)
+History of sarcoidosis syndrome
+Patients must not have evidence or history of veno-occlusive disease or sinusoidal obstruction syndrome
+POEMS syndrome
+Mycosis fungoide/Sezary syndrome
+History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
+History of nephrotic syndrome
+Patients with nevoid BCC syndrome (Gorlin syndrome) should not enroll in this study
+Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis.
+Any history of serotonin syndrome (SS) after receiving  or more serotonergic drugs
+Patients with Downs syndrome
+Patients with Down syndrome
+History of hemolytic-uremic syndrome.
+Erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome
+History of sarcoidosis syndrome
+History of multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome)
+Any history of serotonin syndrome after receiving serotonergic drugs
+Documented history of carcinoid syndrome
+Subjects with history of or active symptoms of carcinoid syndrome
+Any history of serotonin syndrome (SS) after receiving serotonergic drugs
+Known reversible posterior leukoencephalopathy syndrome (RPLS)
+History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
+History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last  months, or alcoholic liver disease;
+Carotid sinus hypersensitivity syndrome.
+Any history of serotonin syndrome (SS) after receiving serotonergic drugs
+Documented history of capillary leak syndrome within  months of study enrollment.
+History of sarcoidosis syndrome
+Patients with respiratory distress syndrome
+Has any history of serotonin syndrome after receiving  or more serotonergic drugs
+Has history of reversible posterior leukoencephalopathy syndrome
+History of sarcoidosis syndrome
+Has a paraneoplastic syndrome other than syndrome of inappropriate antidiuretic hormone secretion (SIADH) (hyponatremia)
+History of sarcoidosis syndrome
+history of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome;
+Has active cytokine release syndrome from CTL infusion
+Down syndrome
+Individuals with Down syndrome
+History of serotonergic syndrome
+Any history of Stevens-Johnson syndrome
+Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible
+Subjects with Gorlin syndrome
+Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
+No history of Stevens Johnsons syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy
+RANDOMIZED PHASE II (ARMS K AND L): No history of Stevens Johnsons syndrome, TENs syndrome, or motor neuropathy
+Patients with active Richter's syndrome (>% large B-cells in marrow).
+History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last  months, or alcoholic liver disease;
+Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome
+POEMS syndrome
+Patients with HNPCC (Lynch Syndrome)
+Has any history of serotonin syndrome after receiving serotonergic drugs
+Down syndrome
+Kostmann syndrome
+Shwachman syndrome
+Patient has a history of Stevens-Johnson-Syndrome (SJS) or Toxic Epidermal Necroloysis (TEN)
+Subject has Acute Respiratory Distress Syndrome (ARDS)
+Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome
+Diagnosis of Down syndrome (Trisomy )
+Patients with any of the following diagnoses:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\r\n* Wilson's disease and any other disorder of copper metabolism\r\n* Juvenile myelomonocytic leukemia (JMML)
+Radiosensitivity syndrome (scleroderma, dermatomyositis, other genetic syndrome that predisposes to adverse radiotherapy complications)
+Patients with a family history or Li-Fraumeni syndrome will not be eligible
+Patients who have experienced bowel perforation, neurologic involvement, Guillain Barr syndrome, Myasthenia Gravis, Steven Johnson syndrome and other intractable events or grade  non-laboratory toxicity
+Patients with a history of toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome are excluded
+Subject has Down syndrome.
+Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
+History of Stevens-Johnson syndrome or toxic epidermal necrolysis syndrome.
+Richter syndrome
+Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome
+Subjects who have history of toxic epidermal necrolysis or Stevens-Johnson syndrome;
+Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement; or
+Had prior serotonin syndrome
+Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
+Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ?  months prior to signing the ICF; or
+Known history or presence of Sweet Syndrome at screening
+History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
+No history of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome
+POEMS syndrome
+Any history of serotonin syndrome after receiving serotonergic drugs.
+History of sarcoidosis syndrome
+Have ongoing or recent (? months) hepatorenal syndrome.
+Patients who have a known inherited syndrome as the cause for hormone over secretion.
+Patients with Cushing's syndrome due to ectopic ACTH secretion or ACTH-independent (adrenal) Cushing's syndrome.
+Have active metabolic or digestive illnesses such as malabsorptive disorders (Crohns, Celiac disease, irritable bowel syndrome [IBS]), renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome
+Patients with any of the following constitutional conditions are not eligible:\r\n* Fanconi anemia\r\n* Shwachman syndrome\r\n* Any other known bone marrow failure syndrome\r\n* Patients with constitutional trisomy  or with constitutional mosaicism of trisomy  \r\nNote: enrollment may occur pending results of clinically indicated studies to exclude these conditions
+Known to have a hypercoagulability syndrome (e.g.: antithrombin III, deficiency, anticardiolipin syndrome etc)
+Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes are not eligible
+History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
+Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosis
+Cushings syndrome
+Li-Fraumeni Syndrome
+History of reversible posterior leukoencephalopathy syndrome (RPLS)
+History of sarcoidosis syndrome.
+Down Syndrome
+History of sarcoidosis syndrome
+Diagnosis of Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
+Individuals with Down syndrome
+Carcinoid Syndrome
+Has a known history of, or active, neurologic paraneoplastic syndrome
+Nephrotic syndrome
+Patients with a known mutation in p (Li Fraumeni syndrome)
+Down syndrome
+Kostmann syndrome
+Shwachman syndrome
+Concomitant genetic syndrome or other known bone marrow failure syndrome
+Down syndrome
+Patients with Down syndrome are excluded.
+Neurologic disease including multiple sclerosis, Eaton-Lambert syndrome, demyelination
+Patients with nevoid BCC syndrome (Gorlin syndrome) may enroll in this study but must meet the criteria for locally advanced or metastatic disease listed above
+Szary syndrome
+Subjects with posterior leukoencephalopathy syndrome
+History of neurological conditions that would confound assessment of treatment-emergent neuropathy other than =< grade  peripheral neuropathy including multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome); diabetes is allowed
+Subjects who have Gorlin syndrome
+Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
+History of sarcoidosis syndrome
+Patients with a family history or Li-Fraumeni syndrome will not be eligible
+Patient has Down syndrome
+Patients with known history of Trisomy  (Down Syndrome), history of congenital immunodeficiency or inherited marrow failure disorder.
+Nephrotic syndrome
+Patients with a known germline mutation of PTPN (Noonans Syndrome) are not eligible
+Immediate family member with a known or suspected Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis).
+History of congenital platelet function defect (e.g., Bernard-Soulier syndrome, Chediak-Higashi syndrome, Glanzmann thrombasthenia, storage pool defect)
+History of hepatic sinusoid obstructive syndrome (venoocculsive disease) within the prior  months.
+Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
+Has known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of IXAZOMIB - Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
+Patients with an immunodeficiency syndrome
+Patients diagnosed with Sezary syndrome; Sezary syndrome is equivalent to mycosis fungoides that develops to stage IVA/B with B (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT
+Patients with any of the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\r\n* Wilson's disease and any other disorder of copper metabolism\r\n* Juvenile myelomonocytic leukemia (JMML)
+Active or a history of Tourettes syndrome or tic disorder
+Patients with Down syndrome
+Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes are not eligible
+Known Mirizzi syndrome.
+History of irritable bowel syndrome (IBS)
+Patients with Sjogren's syndrome
+Ongoing or recent hepatorenal syndrome.
+Patients with diagnosis of chronic fatigue syndrome (CFS)
+Patients with a diagnosis of obesity hypoventilation syndrome
+History of irritable bowel syndrome (IBS)
+Diagnosed or suspected vasospastic disease such as Raynauds syndrome;
+Myelodysplatic Syndrome
+History of Guillain-Barre syndrome
+History of Guillain-Barre syndrome
+Have a history of Guillain-Barre syndrome (GBS)
+Familial short QT syndrome
+Down syndrome
+Short gut syndrome
+History of atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndrome
+Subjects who have Gorlins syndrome
+Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ?  months; or
+Diagnosis of Down's Syndrome
+Individuals with Li Fraumeni syndrome defined as one of the following:\r\n* Carriers of a germline protein  (p) mutation\r\n* Members of families meeting classic Li-Fraumeni syndrome (LFS) criteria by family history without an identifiable p mutation\r\n* Obligate carrier by pedigree (these individuals can be offered testing but are still eligible if they defer); the following examples describe obligate carriers by pedigree\r\n** A child of a parent with known p mutation that is diagnosed with cancer\r\n** An individual with a sibling and a child who are p positive OR\r\n* Individuals with an inherited cancer predisposition syndrome as defined by one of the following:\r\n** Hereditary retinoblastoma with a germline retinoblastoma (Rb) mutation\r\n** Diagnosis of hereditary paraganglioma/pheochromocytoma syndrome with a germline succinate dehydrogenase (SDH) mutation\r\n** Diagnosis of multiple endocrine neoplasia, type  or , with a germline multiple endocrine neoplasia (MEN) mutation\r\n** New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon presentation of symptoms\r\n** Familial neuroblastoma with a germline anaplastic lymphoma kinase (ALK) mutation\r\n** Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD syndrome) or congenital central hypoventilation syndrome (CCHS) with or without a germline pairedlike homeobox B (PHOX B) mutation\r\n** Von Hippel-Lindau with a Von Hippel-Lindau (VHL) mutation\r\n** Women with an abnormal cell-free deoxyribonucleic acid (DNA) test (i.e. a non-invasive prenatal test [NIPT] to detect chromosomal abnormalities) and no cancer diagnosis\r\n** Other rare cancer predisposition syndromes at the discretion of the treating physician and study physicians\r\n* IF APPLICABLE: individuals with any of the above-listed cancer predisposition syndromes (apart from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if they are an obligate carrier by pedigree
+Individuals with Li Fraumeni syndrome defined as one of the following:\r\n* Carriers of a germline p mutation OR\r\n* Members of families meeting classic LFS criteria by family history without an identifiable p mutation OR\r\n* Obligate carrier by pedigree (these individuals can be offered testing but are still eligible if they defer); the following examples describe obligate carriers by pedigree\r\n** A child of a parent with known p mutation that is diagnosed with cancer\r\n** An individual with a sibling and a child who are p positive OR\r\n* Individuals with an inherited cancer predisposition syndrome as defined by one of the following:\r\n** Hereditary retinoblastoma with a germline Rb mutation\r\n** Diagnosis of hereditary paraganglioma/pheochromocytoma syndrome with a germline SDH mutation\r\n** Diagnosis of multiple endocrine neoplasia, type  or , with a germline MEN mutation\r\n** New diagnosis of opsoclonus-myoclonus with a negative cancer work-up upon presentation of symptoms\r\n** Familial neuroblastoma with a germline ALK mutation\r\n** Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD syndrome) or congenital central hypoventilation syndrome (CCHS) with or without a germline PHOX B mutation\r\n** Von Hippel-Lindau with a VHL mutation\r\n** Other rare cancer predisposition syndrome at the discretion of the treating physician and study physicians\r\n* IF APPLICABLE: individuals with any of the above-listed cancer predisposition syndromes (apart from Li Fraumeni syndrome) are likewise eligible in the absence of a known mutation if they are an obligate carrier by pedigree
+History of Stevens-Johnson syndrome
+History of Stevens-Johnson syndrome
+Patients with respiratory distress syndrome
+PATIENT: Patients with respiratory distress syndrome
+Patients with unstable cardiopulmonary conditions or respiratory distress syndrome
+History of Stevens Johnsons syndrome, toxic epidermal necrolysis syndrome (TENs) or motor neuropathy
+Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosis
+Patients with respiratory distress syndrome
+Patients with respiratory distress syndrome
+History of Stevens-Johnson syndrome or toxic epidermal necrolysis syndrome.
+History of Guillain-Barre syndrome or Stevens-Johnson syndrome